Background Despite the effectiveness of the various targeted therapies currently approved
for solid tumors, acquired resistance remains a persistent problem that limits the ultimate …

The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer,
because it regulates the growth and progression of prostate cancer cells. Patients may …

Abstract Background African Americans (AAs) in the United States are known to have a
higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological …

In the past several years, interest in the clinical utility of cell-free DNA as a noninvasive
cancer biomarker has grown rapidly. Success in the development of plasma genotyping …

Background Somatic alterations in circulating tumor DNA (ctDNA) may be associated with
treatment response or prognosis in prostate cancer (PCa). The goal was to characterize …

Liquid biopsies have been receiving tremendous attentions as easy, rapid, and non-invasive
tools for cancer diagnosis. Liquid biopsy can be performed repeatedly for disease …

Prostate cancer is a heterogeneous cancer with widely varying levels of morbidity and
mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and …

Prostate cancer (PC) is the most frequently diagnosed cancer and the second leading cause
of cancer-related death in men in the Western society. Unfortunately, although the vast …

In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor
DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive …

Steroid hormones play a central role in the maintenance and progression of prostate cancer.
The androgen receptor is the primary driver of tumor cell proliferation and is activated by the …